For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>
A clutch of Big Pharma companies is backing a competition to create predictive models that could lead to new targets for cancer drugs. Eli Lilly, Novartis and Pfizer are among the data funders of the competition, which calls for the development of models that show how essential a gene is to the survival of a cancer cell.
AstraZeneca's oncology team aggressively hit the floor in Chicago, publicly brimming with confidence about its top prospects, with global plans to quickly expand its cancer pipeline into an industry leader with multiple combination therapies being pushed into the clinic.
Off-label marketing strikes again. Pfizer agreed to pay $325 million to wrap up claims that its Parke-Davis unit touted the epilepsy drug Neurontin for uses not approved by the FDA, costing healthcare payers millions in unnecessary spending.
Just after Pfizer made a massive drug recall in March, Indian manufacturer Zydus Cadila is now scrambling to pull 10,200 bottles of allergy pills from shelves manufactured by its U.S. unit after the discovery of a blood pressure pill.
Pfizer hasn't given up on pumping Lipitor for sales. Its latest marketing tactic? A replay of its bid to keep scripts coming after the statin drug lost patent protection in 2011. The company is rolling out another copay discount program, Lipitor Choice.
Hold on a minute, says AstraZeneca CEO Pascal Soriot. Now that the dust has settled on Pfizer's failed bid for the U.K. company, Soriot disputes the wisdom of tying his pay--and that of his fellow executives--to the would-be return on that defunct deal.
In March, a U.S. court struck down a key patent for Pfizer's Celebrex, suddenly opening the drug up to copycat rivals. Now, that competition has arrived as the FDA gave the green light to Celebrex copies from Teva Pharmaceutical and Mylan.
Having made the big decisions about how their database of clinical trial investigators will work, collaborators Eli Lilly, Merck and Johnson & Johnson are looking to add more members to a roster already swelled by the arrival of Novartis and Pfizer.
Pfizer may so far have come up blank on the marketed vaccines it hoped to pick up through an AstraZeneca merger. But as it weighs any next M&A-related steps to expand its lineup, it's also embarking on a marketing initiative that could boost uptake of its current star, Prevnar 13.